-
1
-
-
0027506845
-
Epstein-Barr virus infections: Biology, pathogenesis, and management
-
NIH conference
-
Straus SE, Cohen JI, Tosato G, Meier J. NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med. 1993;118(1):45-58.
-
(1993)
Ann Intern Med
, vol.118
, Issue.1
, pp. 45-58
-
-
Straus, S.E.1
Cohen, J.I.2
Tosato, G.3
Meier, J.4
-
2
-
-
49749222804
-
Virus particles in cultured lymphoblasts from Burkitt's lymphoma
-
Epstein M, Achong B, Barr Y. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;1:702-703.
-
(1964)
Lancet
, vol.1
, pp. 702-703
-
-
Epstein, M.1
Achong, B.2
Barr, Y.3
-
3
-
-
0028355939
-
Nasopharyngeal carcinoma: The Epstein-Barr virus association
-
Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol. 1994;21(3):376-381. (Pubitemid 24191597)
-
(1994)
Seminars in Oncology
, vol.21
, Issue.3
, pp. 376-381
-
-
Liebowitz, D.1
-
4
-
-
0034070035
-
The role of EBV in post-transplant malignancies: A review
-
DOI 10.1136/jcp.53.4.248
-
Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol. 2000;53(4):248-254. (Pubitemid 30180395)
-
(2000)
Journal of Clinical Pathology
, vol.53
, Issue.4
, pp. 248-254
-
-
Hopwood, P.1
Crawford, D.H.2
-
5
-
-
0027457370
-
Epstein-Barr virus and Hodgkin's disease: Transcriptional analysis of virus latency in the malignant cells
-
Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177(2):339-349. (Pubitemid 23117083)
-
(1993)
Journal of Experimental Medicine
, vol.177
, Issue.2
, pp. 339-349
-
-
Deacon, E.M.1
Pallesen, G.2
Niedobitek, G.3
Crocker, J.4
Brooks, L.5
Rickinson, A.B.6
Young, L.S.7
-
6
-
-
0027479343
-
Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus
-
Shibata D,Weiss LM, Hernandez AM, Nathwani BN, Bernstein L, Levine AM. Epstein-Barr virusassociated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood. 1993;81(8):2102-2109. (Pubitemid 23106725)
-
(1993)
Blood
, vol.81
, Issue.8
, pp. 2102-2109
-
-
Shibata, D.1
Weiss, L.M.2
Hernandez, A.M.3
Nathwani, B.N.4
Bernstein, L.5
Levine, A.M.6
-
7
-
-
0033581152
-
Detection of Epstein-Barr virus in invasive breast cancers
-
Bonnet M, Guinebretiere JM, Kremmer E, et al. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst. 1999;91(16):1376-1381. (Pubitemid 29399995)
-
(1999)
Journal of the National Cancer Institute
, vol.91
, Issue.16
, pp. 1376-1381
-
-
Bonnet, M.1
Guinebretiere, J.-M.2
Kremmer, E.3
Grunewald, V.4
Benhamou, E.5
Contesso, G.6
Joab, I.7
-
8
-
-
0028099493
-
In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas
-
Yuen ST, Chung LP, Leung SY, Luk IS, Chan SY, Ho J. In situ detection of Epstein-Barr virus in gastric and colorectal adenocarcinomas. Am J Surg Pathol. 1994;18(11):1158-1163. (Pubitemid 24337623)
-
(1994)
American Journal of Surgical Pathology
, vol.18
, Issue.11
, pp. 1158-1163
-
-
Yuen, S.T.1
Chung, L.P.2
Leung, S.Y.3
Luk, I.S.C.4
Chan, S.Y.5
Ho, J.6
-
9
-
-
0030067422
-
Switching viral latency to viral lysis: A novel therapeutic approach for Epstein-Barr virus-associated neoplasia
-
Gutiérrez MI, Judde JG, Magrath IT, Bhatia KG. Switching viral latency to viral lysis: a novel therapeutic approach for Epstein-Barr virus-associated neoplasia. Cancer Res. 1996;56(5):969-972. (Pubitemid 26065387)
-
(1996)
Cancer Research
, vol.56
, Issue.5
, pp. 969-972
-
-
Gutierrez, M.I.1
Judde, J.G.2
Magrath, I.T.3
Bhatia, K.G.4
-
10
-
-
0034870826
-
Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: Pharmacological re-activation of viral target genes with arginine butyrate
-
DOI 10.1034/j.1399-3062.2001.003003177.x
-
Mentzer SJ, Perrine SP, Faller DV. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological reactivation of viral target genes with arginine butyrate. Transpl Infect Dis. 2001;3(3):177-185. (Pubitemid 32756700)
-
(2001)
Transplant Infectious Disease
, vol.3
, Issue.3
, pp. 177-185
-
-
Mentzer, S.J.1
Perrine, S.P.2
Faller, D.V.3
-
11
-
-
0041465971
-
Virally targeted therapies for EBV-associated malignancies
-
DOI 10.1038/sj.onc.1206548
-
Israel BF, Kenney SC. Virally targeted therapies for EBV-associated malignancies. Oncogene. 2003;22(33):5122-5130. (Pubitemid 37059593)
-
(2003)
Oncogene
, vol.22
, Issue.33 REV. ISS. 2
, pp. 5122-5130
-
-
Israel, B.F.1
Kenney, S.C.2
-
12
-
-
0032104738
-
Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma
-
DOI 10.1006/bcmd.1998.0178
-
Mentzer SJ, Fingeroth J, Reilly JJ, Perrine SP, Faller DV. Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus- associated lymphoma. Blood Cells Mol Dis. 1998;24(2):114-123. (Pubitemid 28365731)
-
(1998)
Blood Cells, Molecules and Diseases
, vol.24
, Issue.2
, pp. 114-123
-
-
Mentzer, S.J.1
Fingeroth, J.2
Reilly, J.J.3
Perrine, S.P.4
Faller, D.V.5
-
13
-
-
0034667460
-
Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: A potential method for treating EBV-positive malignancies
-
Westphal EM, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res. 2000; 60(20):5781-5788.
-
(2000)
Cancer Res
, vol.60
, Issue.20
, pp. 5781-5788
-
-
Westphal, E.M.1
Blackstock, W.2
Feng, W.3
Israel, B.4
Kenney, S.C.5
-
14
-
-
0034954624
-
Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues
-
DOI 10.1128/AAC.45.7.2082-2091.2001
-
Moore SM, Cannon JS, Tanhehco YC, Hamzeh FM, Ambinder RF. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother. 2001; 45(7):2082-2091. (Pubitemid 32591702)
-
(2001)
Antimicrobial Agents and Chemotherapy
, vol.45
, Issue.7
, pp. 2082-2091
-
-
Moore, S.M.1
Cannon, J.S.2
Tanhehco, Y.C.3
Hamzeh, F.M.4
Ambinder, R.F.5
-
15
-
-
17444411923
-
Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo
-
DOI 10.1128/JVI.79.9.5875-5879.2005
-
Daibata M, Bandobashi K, Kuroda M, Imai S, Miyoshi I, Taguchi H. Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo. J Virol. 2005;79(9):5875- 5879. (Pubitemid 40548258)
-
(2005)
Journal of Virology
, vol.79
, Issue.9
, pp. 5875-5879
-
-
Daibata, M.1
Bandobashi, K.2
Kuroda, M.3
Imai, S.4
Miyoshi, I.5
Taguchi, H.6
-
16
-
-
0842326026
-
Lytic Induction Therapy for Epstein-Barr Virus-Positive B-Cell Lymphomas
-
DOI 10.1128/JVI.78.4.1893-1902.2004
-
Feng WH, Hong G, Delecluse HJ, Kenney SC.Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol. 2004;78(4): 1893-1902. (Pubitemid 38176721)
-
(2004)
Journal of Virology
, vol.78
, Issue.4
, pp. 1893-1902
-
-
Feng, W.-H.1
Hong, G.2
Delecluse, H.-J.3
Kenney, S.C.4
-
17
-
-
53549087773
-
Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors
-
Fu DX, Tanhehco Y, Chen J, et al. Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors. Nat Med. 2008; 14(10):1118-1122.
-
(2008)
Nat Med
, vol.14
, Issue.10
, pp. 1118-1122
-
-
Fu, D.X.1
Tanhehco, Y.2
Chen, J.3
-
18
-
-
33947275876
-
A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies
-
DOI 10.1182/blood-2006-01-024703
-
Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109(6):2571-2578. (Pubitemid 46425904)
-
(2007)
Blood
, vol.109
, Issue.6
, pp. 2571-2578
-
-
Perrine, S.P.1
Hermine, O.2
Small, T.3
Suarez, F.4
O'Reilly, R.5
Boulad, F.6
Fingeroth, J.7
Askin, M.8
Levy, A.9
Mentzer, S.J.10
Di, N.M.11
Gianni, A.M.12
Klein, C.13
Horwitz, S.14
Faller, D.V.15
-
19
-
-
0035063182
-
Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connections between cancer and chromatin
-
Wade PA. Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet. 2001;10(7):693-698. (Pubitemid 32331577)
-
(2001)
Human Molecular Genetics
, vol.10
, Issue.7
, pp. 693-698
-
-
Wade, P.A.1
-
20
-
-
0035724413
-
The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3
-
DOI 10.1128/MCB.21.18.6091-6101.2001
-
Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol. 2001; 21(18):6091-6101. (Pubitemid 34263509)
-
(2001)
Molecular and Cellular Biology
, vol.21
, Issue.18
, pp. 6091-6101
-
-
Guenther, M.G.1
Barak, O.2
Lazar, M.A.3
-
21
-
-
0344407016
-
Histone deacetylases: Unique players in shaping the epigenetic histone code
-
Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci. 2003;983:84-100. (Pubitemid 36399322)
-
(2003)
Annals of the New York Academy of Sciences
, vol.983
, pp. 84-100
-
-
Thiagalingam, S.1
Cheng, K.-H.2
Lee, H.J.3
Mineva, N.4
Thiagalingam, A.5
Ponte, J.F.6
-
22
-
-
4143140016
-
Histone deacetylase inhibitors open new doors in cancer therapy
-
DOI 10.1016/j.bcp.2004.05.034, PII S0006295204003697
-
McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol. 2004;68(6):1139-1144. (Pubitemid 39094279)
-
(2004)
Biochemical Pharmacology
, vol.68
, Issue.6
, pp. 1139-1144
-
-
McLaughlin, F.1
La, T.N.B.2
-
23
-
-
77649171884
-
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
-
Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5.
-
(2010)
J Hematol Oncol
, vol.3
, pp. 5
-
-
Tan, J.1
Cang, S.2
Ma, Y.3
Petrillo, R.L.4
Liu, D.5
-
24
-
-
67449127082
-
Clinical studies of histone deacetylase inhibitors
-
Prince HM, Bishton MJ, Harrison SJ. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res. 2009;15(12):3958-3969.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.12
, pp. 3958-3969
-
-
Prince, H.M.1
Bishton, M.J.2
Harrison, S.J.3
-
25
-
-
36148950997
-
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
-
DOI 10.1634/theoncologist.12-10-1247
-
Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247-1252. (Pubitemid 350106355)
-
(2007)
Oncologist
, vol.12
, Issue.10
, pp. 1247-1252
-
-
Mann, B.S.1
Johnson, J.R.2
Cohen, M.H.3
Justice, R.4
Pazdur, R.5
-
26
-
-
77954884940
-
Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
-
Grant C, Rahman F, Piekarz R, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10(7):997-1008.
-
(2010)
Expert Rev Anticancer Ther
, vol.10
, Issue.7
, pp. 997-1008
-
-
Grant, C.1
Rahman, F.2
Piekarz, R.3
-
27
-
-
0014139019
-
Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line
-
Hinuma Y, Konn M, Yamaguchi J, Wudarski DJ, Blakeslee JR Jr, Grace JT Jr. Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol. 1967; 1(5):1045-1051.
-
(1967)
J Virol
, vol.1
, Issue.5
, pp. 1045-1051
-
-
Hinuma, Y.1
Konn, M.2
Yamaguchi, J.3
Wudarski, D.J.4
Blakeslee Jr., J.R.5
Grace Jr., J.T.6
-
28
-
-
0014304475
-
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines
-
Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968;28(7): 1300-1310.
-
(1968)
Cancer Res
, vol.28
, Issue.7
, pp. 1300-1310
-
-
Klein, E.1
Klein, G.2
Nadkarni, J.S.3
Nadkarni, J.J.4
Wigzell, H.5
Clifford, P.6
-
29
-
-
0017237293
-
Structure of HLA antigens: Amino-acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations
-
Terhorst C, Parham P, Mann DL, Strominger JL. Structure of HLA antigens: amino-acid and carbohydrate compositions and NH2-terminal sequences of four antigen preparations. Proc Natl Acad Sci U S A. 1976;73(3):910-914.
-
(1976)
Proc Natl Acad Sci U S A
, vol.73
, Issue.3
, pp. 910-914
-
-
Terhorst, C.1
Parham, P.2
Mann, D.L.3
Strominger, J.L.4
-
30
-
-
0016835245
-
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma
-
Menezes J, Leibold W, Klein G, Clements G. Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine. 1975;22(4):276-284.
-
(1975)
Biomedicine
, vol.22
, Issue.4
, pp. 276-284
-
-
Menezes, J.1
Leibold, W.2
Klein, G.3
Clements, G.4
-
31
-
-
0032818721
-
Somatic mutations and intraclonal variations in the rearranged V(K) genes of B-non-Hodgkin's lymphoma cell lines
-
Gabay C, Ben-Bassat H, Schlesinger M, Laskov R. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur J Haematol. 1999;63(3): 180-191. (Pubitemid 29406735)
-
(1999)
European Journal of Haematology
, vol.63
, Issue.3
, pp. 180-191
-
-
Gabay, C.1
Ben-Bassat, H.2
Schlesinger, M.3
Laskov, R.4
-
32
-
-
64049106355
-
Synthesis and histone deacetylase inhibitory activity of largazole analogs: Alteration of the zinc-binding domain and macrocyclic scaffold
-
Bowers AA, West N, Newkirk TL, et al. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold. Org Lett. 2009; 11(6):1301-1304.
-
(2009)
Org Lett
, vol.11
, Issue.6
, pp. 1301-1304
-
-
Bowers, A.A.1
West, N.2
Newkirk, T.L.3
-
33
-
-
33845599154
-
Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents
-
DOI 10.1016/j.bcmd.2006.10.008, PII S1079979606002336
-
Ghosh SK, Forman LW, Akinsheye I, Perrine SP, Faller DV. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents. Blood Cells Mol Dis. 2007;38(1):57-65. (Pubitemid 44960868)
-
(2007)
Blood Cells, Molecules, and Diseases
, vol.38
, Issue.1
, pp. 57-65
-
-
Ghosh, S.K.1
Forman, L.W.2
Akinsheye, I.3
Perrine, S.P.4
Faller, D.V.5
-
34
-
-
46049100010
-
Total synthesis and molecular target of largazole, a histone deacetylase inhibitor
-
DOI 10.1021/ja8013727
-
Ying Y, Taori K, Kim H, Hong J, Luesch H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor. J Am Chem Soc. 2008;130(26):8455-8459. (Pubitemid 351898566)
-
(2008)
Journal of the American Chemical Society
, vol.130
, Issue.26
, pp. 8455-8459
-
-
Ying, Y.1
Taori, K.2
Kim, H.3
Hong, J.4
Luesch, H.5
-
35
-
-
0020683890
-
Effect of arabinofuranosylthymine on the replication of Epstein-Barr virus and relationship with a new induced thymidine kinase activity
-
Ooka T, Calender A, de Turenne M, Daillie J. Effect of arabinofuranosylthymine on the replication of Epstein-Barr virus and relationship with a new induced thymidine kinase activity. J Virol. 1983;46(1):187-195. (Pubitemid 13161258)
-
(1983)
Journal of Virology
, vol.46
, Issue.1
, pp. 187-195
-
-
Ooka, T.1
Calender, A.2
De Turenne, M.3
Daillie, J.4
-
36
-
-
77950850768
-
The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production
-
Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production. J Virol. 2010;84(9):4534-4542.
-
(2010)
J Virol
, vol.84
, Issue.9
, pp. 4534-4542
-
-
Meng, Q.1
Hagemeier, S.R.2
Fingeroth, J.D.3
Gershburg, E.4
Pagano, J.S.5
Kenney, S.C.6
-
37
-
-
33744484523
-
Epstein-Barr virus (EBV) and its associated human cancers - Genetics, epigenetics, pathobiology and novel therapeutics
-
DOI 10.2741/2000
-
Tao Q, Young LS, Woodman CB, Murray PG. Epstein-Barr virus (EBV) and its associated human cancers - genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci. 2006;11: 2672-2713. (Pubitemid 43806572)
-
(2006)
Frontiers in Bioscience
, vol.11
, Issue.SUPPL. 2
, pp. 2672-2713
-
-
Tao, Q.1
Young, L.S.2
Woodman, C.B.J.3
Murray, P.G.4
-
38
-
-
0031724984
-
The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase
-
Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother. 1998; 42(11):2923-2931. (Pubitemid 28501227)
-
(1998)
Antimicrobial Agents and Chemotherapy
, vol.42
, Issue.11
, pp. 2923-2931
-
-
Gustafson, E.A.1
Chillemi, A.C.2
Sage, D.R.3
Fingeroth, J.D.4
-
39
-
-
84863078906
-
Short-term exposure to arginine butyrate, in combination with ganciclovir, is as effective as continuous exposure for virus-targeted therapy of EBV-positive lymphomas
-
[abstract]
-
Faller DV, Ghosh S, Feldman T, et al. Short-term exposure to arginine butyrate, in combination with ganciclovir, is as effective as continuous exposure for virus-targeted therapy of EBV-positive lymphomas [abstract]. Blood. 2009;114(1):4754.
-
(2009)
Blood
, vol.114
, Issue.1
, pp. 4754
-
-
Faller, D.V.1
Ghosh, S.2
Feldman, T.3
-
40
-
-
34848883438
-
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies
-
DOI 10.1158/1078-0432.CCR-07-0791
-
Kummar S, Gutierrez M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res. 2007;13(18 pt 1):5411-5417. (Pubitemid 47510368)
-
(2007)
Clinical Cancer Research
, vol.13
, Issue.18
, pp. 5411-5417
-
-
Kummar, S.1
Gutierrez, M.2
Gardner, E.R.3
Donovan, E.4
Hwang, K.5
Eun, J.C.6
Lee, M.-J.7
Maynard, K.8
Kalnitskiy, M.9
Chen, A.10
Melillo, G.11
Ryan, Q.C.12
Conley, B.13
Figg, W.D.14
Trepel, J.B.15
Zwiebel, J.16
Doroshow, J.H.17
Murgo, A.J.18
-
41
-
-
34447101115
-
MS-275, a potent orally available inhibitor of histone deacetylases-The development of an anticancer agent
-
DOI 10.1016/j.biocel.2007.02.009, PII S135727250700057X
-
Hess-Stumpp H, Bracker TU, Henderson D, Politz O. MS-275, a potent orally available inhibitor of histone deacetylases - the development of an anticancer agent. Int J Biochem Cell Biol. 2007;39(7-8):1388-1405. (Pubitemid 47031032)
-
(2007)
International Journal of Biochemistry and Cell Biology
, vol.39
, Issue.7-8
, pp. 1388-1405
-
-
Hess-Stumpp, H.1
Bracker, T.U.2
Henderson, D.3
Politz, O.4
-
42
-
-
77951884767
-
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castrationresistant prostate cancer
-
Rathkopf D, Wong BY, Ross RW, et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castrationresistant prostate cancer. Cancer Chemother Pharmacol. 2010;66(1):181-189.
-
(2010)
Cancer Chemother Pharmacol
, vol.66
, Issue.1
, pp. 181-189
-
-
Rathkopf, D.1
Wong, B.Y.2
Ross, R.W.3
-
43
-
-
0023235414
-
Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells
-
Biggin M, Bodescot M, Perricaudet M, Farrell P. Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells. J Virol. 1987;61(10): 3120-3132. (Pubitemid 17131493)
-
(1987)
Journal of Virology
, vol.61
, Issue.10
, pp. 3120-3132
-
-
Biggin, M.1
Bodescot, M.2
Perricaudet, M.3
Farrell, P.4
-
44
-
-
0021415065
-
The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus
-
Jones MD, Foster L, Sheedy T, Griffin BE. The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J. 1984;3(4):813-821.
-
(1984)
EMBO J
, vol.3
, Issue.4
, pp. 813-821
-
-
Jones, M.D.1
Foster, L.2
Sheedy, T.3
Griffin, B.E.4
-
45
-
-
43049119236
-
The use of diversity profiling to characterize chemical modulators of the histone deacetylases
-
Blackwell L, Norris J, Suto CM, Janzen WP. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci. 2008;82(21-22):1050-1058.
-
(2008)
Life Sci
, vol.82
, Issue.21-22
, pp. 1050-1058
-
-
Blackwell, L.1
Norris, J.2
Suto, C.M.3
Janzen, W.P.4
-
46
-
-
77249087051
-
Chemical phylogenetics of histone deacetylases
-
Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6(3):238-243.
-
(2010)
Nat Chem Biol
, vol.6
, Issue.3
, pp. 238-243
-
-
Bradner, J.E.1
West, N.2
Grachan, M.L.3
-
47
-
-
12044258531
-
Butyrate-induced reactivation of the fetal globin genes: A molecular treatment for the beta-hemoglobinopathies
-
Perrine SP, Faller DV. Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies. Experientia. 1993;49(2):133-137. (Pubitemid 23063413)
-
(1993)
Experientia
, vol.49
, Issue.2
, pp. 133-137
-
-
Perrine, S.P.1
Faller, D.V.2
-
48
-
-
0031660978
-
Epstein-barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata
-
Komano J, Sugiura M, Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol. 1998;72(11):9150-9156. (Pubitemid 28471860)
-
(1998)
Journal of Virology
, vol.72
, Issue.11
, pp. 9150-9156
-
-
Komano, J.1
Sugiura, M.2
Takada, K.3
|